Cancer: slaying the nine-headed Hydra. Ann Oncol 2023 Jan;34(1):61-69
Date
08/06/2022Pubmed ID
35931318Pubmed Central ID
PMC10923524DOI
10.1016/j.annonc.2022.07.010Scopus ID
2-s2.0-85137384226 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Modern medicine continues to evolve, and the treatment armamentarium for various diseases grows more individualized across a breadth of medical disciplines. Cure rates for infectious diseases that were previously pan-fatal approach 100% because of the identification of the specific pathogen(s) involved and the use of appropriate combinations of drugs, where needed, to completely extinguish infection and hence prevent emergence of resistant strains. Similarly, with the assistance of technologies such as next-generation sequencing and immunomic analysis as part of the contemporary oncology armory, therapies can be tailored to each tumor. Importantly, molecular interrogation has revealed that metastatic cancers are distinct from each other and complex. Therefore, it is conceivable that rational personalized drug combinations will be needed to eradicate cancers, and eradication will be necessary to mitigate clonal evolution and resistance.
Author List
Adashek JJ, Subbiah V, Westphalen CB, Naing A, Kato S, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsHumans
Hydra
Medical Oncology
Neoplasms